When were the AGIO performance share units originally granted?

The performance share units were originally granted on March 5, 2025. These awards are structured to vest only if specified clinical and research milestones are achieved, aligning the executive’s potential share ownership with longer-term company performance.

What milestone timing affects vesting of AGIO’s performance share units?

The compensation & people committee determined a specified research milestone was met as of June 18, 2026. Shares tied to that milestone are scheduled to vest on December 31, 2027, provided the recipient continues to serve the company through that date.

Agios (NASDAQ: AGIO) grants Viswanadhan 6,000 RSU and performance share units

Q: What are the terms of the performance share units reported for AGIO?

The performance share units represent rights to receive 3,000 shares of common stock. They vest upon achievement of three specified clinical and research milestones set by the compensation & people committee or board, linking executive compensation to defined performance goals.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. reported that Chief Strategy and Operations officer Krishnan Viswanadhan acquired equity-based compensation on June 18, 2026. He received 3,000 restricted stock units, each representing a contingent right to one share of common stock, and a further 3,000 performance share units tied to clinical and research milestones. The performance share units were originally granted on March 5, 2025, and the compensation & people committee determined that the performance criteria for a specified research milestone were met as of June 18, 2026. Shares related to that milestone are scheduled to vest on December 31, 2027, subject to his continued service.

Insider Trade Summary

3,000 shares exercised/converted

Mixed 2 txns

Insider Viswanadhan Krishnan

Role Chief Strategy and Operations

Type	Security	Shares	Price	Value
Exercise	Performance share units	3,000	$0.00	--
Grant/Award	Restricted stock units	3,000	$0.00	--

Holdings After Transaction: Performance share units — 9,000 shares (Direct, null); Restricted stock units — 3,000 shares (Direct, null)

Footnotes (1)

Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Key Figures

Restricted stock units granted: 3,000 units Performance share units tied to milestone: 3,000 units Derivative exercises: 3,000 shares +3 more

6 metrics

Restricted stock units granted 3,000 units Equity award to Chief Strategy and Operations officer

Performance share units tied to milestone 3,000 units Contingent right to common stock upon milestone vesting

Derivative exercises 3,000 shares Exercise or conversion of performance share units

Total derivative transactions 2 transactions Both classified as acquisitions of derivative securities

Vesting date for milestone-related shares December 31, 2027 Subject to continued service requirement

Performance grant date March 5, 2025 Original grant date of performance share units

Key Terms

Restricted stock units, Performance share units, contingent right, clinical and research milestones, +1 more

5 terms

Restricted stock units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each performance stock unit represents a contingent right to receive one share"

clinical and research milestones financial

"vesting of underlying shares upon the achievement of three specified clinical and research milestones"

compensation & people committee financial

"milestones established by the compensation & people committee, or board of directors"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:18 PM Accepted by SEC EDGAR 06/23/2026 - 05:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Viswanadhan Krishnan

(Last)

(First)

(Middle)

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Strategy and Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance share units	⁽¹⁾	06/18/2026		M			3,000	⁽²⁾	⁽²⁾	Common stock	3,000	$0	9,000	D
Restricted stock units	⁽³⁾	06/18/2026		A		3,000		⁽²⁾	⁽²⁾	Common stock	3,000	$0	3,000	D

Explanation of Responses:

1. Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.

2. Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.

3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Remarks:

	/s/ William Cook, as Attorney in Fact for Krishnan Viswanadhan	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did AGIO executive Krishnan Viswanadhan report?

Krishnan Viswanadhan reported equity awards, not open-market trades. He received 3,000 restricted stock units and 3,000 performance share units, each convertible into one share of Agios common stock, as part of his compensation package.

How many restricted stock units did AGIO grant to Krishnan Viswanadhan?

Agios granted Krishnan Viswanadhan 3,000 restricted stock units. Each unit represents a contingent right to receive one share of Agios common stock, typically subject to time-based vesting and continued service conditions set by the company.

Does the AGIO Form 4 show any insider stock sales or purchases?

The Form 4 does not show open-market stock sales or purchases. It reflects equity compensation events: a grant of restricted stock units and performance share units linked to milestone achievement, both classified as acquisitions rather than discretionary market trades.